Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 1173 Results

Title
Intervention Indication Therapeutic Area Year Actions
Canakinumab adjuvant therapy for treating completely
resected non-small-cell lung cancer
Canakinumab (Ilaris; ACZ885) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2022 View  |  Download
Canakinumab (ILARIS) for Cardiovascular risk reduction – Add on therapy Canakinumab (Ilaris; ACZ885) Cardiovascular disease (CVD) Cardiovascular System 2017 View  |  Download
Canagliflozin for type 2 diabetes mellitus in children and adolescents Canagliflozin (Invokana; canagliflozin hemihydrate) Type 2 diabetes Endocrine Nutritional and Metabolic Disorders 2023 View  |  Download
Canagliflozin for chronic kidney disease in adult patients with type 2 diabetes mellitus Canagliflozin (Invokana; canagliflozin hemihydrate) Diabetic nephropathy Endocrine Nutritional and Metabolic Disorders , Nephrology 2019 View  |  Download
CAEL-101 for treating amyloid light chain amyloidosis CAEL-101 Amyloid light chain amyloidosis Endocrine Nutritional and Metabolic Disorders 2022 View  |  Download
Cabozantinib with nivolumab and ipilimumab for previously untreated advanced or metastatic renal cell carcinoma Cabozantinib (XL-184; Cabometyx; Cometriq; XL 184) , Ipilimumab (Yervoy; BMS 734016; MDX 101) , Nivolumab (Opdivo; BMS-936558; ONO-4538) Renal cell carcinoma (RCC) Renal Cancer 2023 View  |  Download
Cabozantinib with atezolizumab for treating metastatic castration-resistant prostate cancer after one novel hormonal therapy Atezolizumab (Tecentriq; MPDL3280A) , Cabozantinib (XL-184; Cabometyx; Cometriq; XL 184) Prostate cancer Haematological Cancer and Lymphomas , Oncology 2023 View  |  Download
Cabozantinib in combination with atezolizumab for advanced hepatocellular carcinoma –first line Atezolizumab (Tecentriq; MPDL3280A) , Cabozantinib (XL-184; Cabometyx; Cometriq; XL 184) Hepatocellular carcinoma (HCC) Gastrointestinal Cancer 2021 View  |  Download
Cabozantinib for treating differentiated thyroid cancer Cabozantinib (XL-184; Cabometyx; Cometriq; XL 184) Differentiated thyroid cancer (DTC) Head and Neck Cancer 2021 View  |  Download
Cabozantinib for Hepatocellular Carcinoma Cabozantinib (XL-184; Cabometyx; Cometriq; XL 184) Hepatocellular carcinoma (HCC) Gastrointestinal Cancer 2017 View  |  Download
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications